

Food & Function

Linking the chemistry and physics of food with health and nutrition

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: G. Gerardi, M. Cavia-Saiz, M. D. Rivero-Perez, M. L. González-SanJosé and P. Muñiz, *Food Funct.*, 2020, DOI: 10.1039/C9FO01743G.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

1 **Dose-response effect on polyphenols bioavailability after intake of white and red wine pomace**
2 **products by Wistar rats**

3
4 Gisela Gerardi, Mónica Cavia-Saiz, M. Dolores Rivero-Pérez, María Luisa González-SanJosé and Pilar
5 Muñiz*

6
7 Department of Biotechnology and Food Science, Faculty of Sciences, University of Burgos, Plaza Misael
8 Bañuelos, 09001, Burgos, Spain.

9
10 ***Corresponding author:** Dra. Pilar Muñiz Rodríguez, Plaza Misael Bañuelos, Facultad de Ciencias,
11 Departamento de Biotecnología y Ciencia de los Alimentos, 09001, Burgos, Spain.

12 **E-mail:** pmuniz@ubu.es

13 **Phone:** +34-947258800 Ext. 8210


14 **Fax:** +34-947258831

15
16 **E-mail addresses:** Gisela Gerardi (mggerardi@ubu.es), Monica Cavia-Saiz (monicacs@ubu.es), María D.
17 Rivero-Pérez (drivero@ubu.es), María L. González-SanJosé (marglez@ubu.es), Pilar Muñiz
18 (pmuniz@ubu.es).

19
20 **ORCID iDs:**

21 Gisela Gerardi  <https://orcid.org/0000-0003-2510-0422>

22 Monica Cavia-Saiz  <https://orcid.org/0000-0001-5132-381X>

23 María D. Rivero-Pérez  <https://orcid.org/0000-0003-0907-4009>

24 María L. González-SanJosé  <https://orcid.org/0000-0003-2973-7287>

25 Pilar Muñiz  <https://orcid.org/0000-0002-9306-0082>

26

27

28

29

30

31 **Abstract**

32 Wine pomace by-products are an important source of phenolic acids with significant health benefits.

View Article Online
DOI: 10.1039/C9FO01743G

33 However, phenolic acid bioavailability *in vivo* has been little studied and there are few comparative studies
34 on bioavailability between red and white wine pomaces and the effect of different doses of intake. The
35 qualitative and quantitative profile of phenolic acid metabolites in plasma and urine samples from Wistar rats
36 was performed by gas chromatography/mass detection, after oral administration of four doses (50, 100, 150,
37 and 300 mg) of both the red and the white wine pomace products (rWPP and wWPP, respectively). The
38 antioxidant capacity of the plasma samples assessed by both the ABTS and the FRAP levels were also
39 evaluated. The results showed that neither the bioavailability nor the antioxidant capacity *in vivo* of the
40 rWPP increased at high doses. However, both parameters were dependent on the intake of the wWPP.

41

42

43 **Keywords:** Phenolic acids, bioavailability, red wine pomace, white wine pomace, antioxidant.

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60 **1 Introduction**

61 Agroindustrial food wastes and by-products such as grape pomace products can be used to the development

62 of functional foods. The polyphenol content of grape pomace and its beneficial effects depends on different
63 factors such as grape variety, winery process, type of grape pomace (skins, seeds or entire grape pomace,
64 pure polyphenol extract or grape pomace products), and polyphenol bioavailability^{1,2}.

65 The properties of polyphenols have been associated with antioxidant, anti-inflammatory², anti-aging³, and
66 anti-cancer⁴ effects, as well as the prevention of different diseases^{5,6}. Nevertheless, it is important to
67 consider polyphenol bioavailability; it is known that not all of the polyphenols present in grape pomace will
68 be necessarily bioactive in the organism. Their intrinsic activity is dependent on the intestinal absorption and
69 bioactive metabolites are the result of digestive and hepatic metabolic processes and differ from native
70 polyphenols⁷. In this sense, phenolic acids of wine pomace include polymers, esters, and glycosides that are
71 hydrolysed by gastrointestinal enzymes and further modified by the intestinal microbiota⁸. The
72 metabolization of these compounds increases their hydrophilicity and facilitates urinary and/or biliary
73 elimination⁷. Furthermore, some studies reported that wine pomace by-products are a good source of dietary
74 fiber and polyphenols^{9,10}.

75 However, very few studies have evaluated the effect of the intake of different doses of wine pomaces and the
76 differences between red and white wine pomaces bioavailabilities. In previous studies, we observed that high
77 levels of phenolic acids in plasma are associated with a high prevention of lipid peroxidation and a high
78 nitric oxide bioavailability in Wistar rats after oral administration of a single oral dose of 300 mg/kg BW of
79 red wine pomace product (rWPP)¹¹. Considering that the health effects of the polyphenols could depend on
80 their dietary intake, is important to evaluate if a higher intake of WPP will increase the polyphenol
81 bioavailability. In this sense, the aims of our study were to fill that gap by investigating the bioavailability
82 and the antioxidant capacity of different oral doses of red and white pomace products (rWPP and wWPP,
83 respectively) following oral administration to rats in a 6 hour study.

84

85

86

87

88

89 **2 Materials and methods**

90 **2.1 Chemicals**

View Article Online
DOI: 10.1039/C9FO01743G

91 ABTS, 1-hidroxy-2-naphtoic acid (internal standard), 2,4,6-Tris (2-pyridyl)-S-Triazine (TPTZ), 6-hydroxyl-
92 2,5,7,8-tetramethyl-2-carboxylic acid (Trolox), β -glucosidase from almonds (≥ 2 U/mg), β -glucuronidase
93 from *Helix pomatia* (≥ 100000 U/mL), ethyl acetate, gallic acid, formic acid, methanol, N,O-bis
94 (trimethylsilyl) trifluoroacetamide with 1% trimethylchlorosilane (BSTFA+TMS), Pyridine anhydrous
95 (99.8%), and all phenolic compound standards were purchased from Sigma Aldrich (St. Louis, MO, USA).
96 Folin-Ciocalteau reagent, FeCl₃, FeSO₄, Na₂CO₃ were obtained from Panreac Química, S.L.U. (Barcelona,
97 Spain).

98 **2.2 Red and White Wine Pomace Products**

99 Red and white wine pomace-derived products from the vinification of *Vitis vinifera L. cv. Tempranillo* and
100 *Verdejo* (rWPP and wWPP, respectively) were prepared at the University of Burgos according to a
101 previously described method^{12,13}.

102 **2.3 Animal experiments**

103 Experimentation with live animals was approved by the Ethics Committee for Experimental Animal Care at
104 the University Hospital of Burgos (ref. CEBA 13) and it was carried out in accordance with the Spanish and
105 European laws (Royal Decree 53/2013 of the Spanish Ministry of agriculture, Food and Environment and
106 Ministry of Economy and Competitiveness, and European Directive 2010/63/EU).

107 **2.3.1 Animals**

108 Male Wistar rats (*Rattus norvegicus*; $n = 30$; age, 12 weeks; weight: 423 ± 42 g) were obtained from the
109 Animal Research and Welfare Service of Valladolid (SIBA, Valladolid, Spain). The rats were left to
110 acclimatize for 2 weeks. The room temperature was maintained at 21 ± 2 °C and humidity at 40 ± 10 %, with
111 a 12:12-h light:dark cycle and free access to food (A04 Safe Diet) and water. The animals were placed for 1
112 hour in metabolic cages and, for adaptation purposes, were subjected to human manipulation during the
113 weeks before the experiments. All procedures were designed to limit the number of animals used by leaving
114 the animals to rest for 2 wk between experiments.

115 **2.3.2 Experimental Design**

116 rWPP and wWPP doses at 50, 100, 150, and 300 mg/kg of body weight (2 mL of water) was administrated to
117 the rats by oral gavage after food deprivation for 8h with free access to water. Rats were individually placed

118 in metabolic cages and urine was collected both before and after WPP administration in 2-hourly intervals (-
119 2-0h, 0-2h, 2-4h and 4-6h). Aliquots of these urine samples were stored frozen at -80°C until analysis. Blood
120 samples were collected at baseline (0h) and post-WPP administration (2h, 4h, and 6h). Blood samples were
121 taken by lateral saphenous venipuncture with a 23G needle and held in Vacutainer tubes containing
122 sodium/lithium heparin as anticoagulant and were centrifuged at 1500g for 10 minutes to recover the plasma.
123 The volume of blood taken for each rat was never in excess of 1.2 mL according to the NC3Rs
124 recommendations (4.4% blood volume removed) ¹⁴.

View Article Online
DOI: 10.1039/C9FO01743G

125 **2.4 Antioxidant Capacity**

126 Total antioxidant capacity of the rWPP and wWPP products were determined by QUENCHER-methods
127 described previously ¹³. Additionally, total antioxidant capacity of urine and plasma samples was measured
128 by FRAP and ABTS methods ¹¹.

129 **2.4.1 Quencher Total Antioxidant Capacity of the Wine Pomace Products (WPPs)**

130 QUENCHER-TAC (Q-) versions ¹³ of three conventional total antioxidant capacity (TAC) assays were
131 performed (Folin-Ciocalteu index, ABTS and FRAP were selected to evaluate the TAC of each fraction). For
132 all determinations a sample mass of WPP (1 ± 0.005 mg) was used.

133 - Quencher Folin-Ciocalteu assay (Q-FC): WPPs were mixed with equal volumes (0.2 mL) of Milli-Q water
134 and Folin-Ciocalteu reagent and, after 5 min, 4 mL of 0.7 M Na₂CO₃ solution was added and the mixture
135 made up to a final volume of 10 mL with Milli-Q water. After incubation for 1 h in the dark with continuous
136 stirring, the supernatant was separated and the absorbance at 750 nm was measured in a UV-vis
137 spectrophotometer U- 2000 (Hitachi, Ltd., Hubbardston, MA, USA). A dose-response curve was plotted
138 using different quantities of gallic acid as the standard.

139 - Quencher ABTS assay (Q-ABTS): WPPs were mixed with 10mL of the ABTS⁺ working solution and
140 incubated 30 min in the dark in an orbital shaker. Then, the supernatant was separated and the absorbance
141 was measured at 734 nm. A linear calibration curve was obtained with different amounts of Trolox as per the
142 relevant standard.

143 - Quencher FRAP assay (Q-FRAP): WPPs were mixed with 10 ml of the FRAP solution and incubated at 37
144 °C for 30 min with continuous stirring. Absorbance was measured at 593 nm. The results were expressed as
145 μmol of iron (II) equivalents/g of product (Fe(II)E/g) using linear calibration obtained with different amounts
146 of FeSO₄.

147 **2.4.2 Total antioxidant capacity of plasma and urine samples**

148 The total antioxidant capacity of both the plasma and the urine samples was assayed using two independent
149 determinations: the ferric reducing antioxidant power (FRAP) and the ABTS methods previously described
150 above ¹¹. Briefly, a volume of 980 μL of the FRAP solution was added to 20 μL of plasma or urine samples
151 and incubated at 37 °C for 30 min and absorbance was measured at 593 nm. The results were expressed as
152 mM of iron (II) equivalents (Fe(II)) using a linear calibration obtained with different amounts of FeSO₄. For
153 the ABTS method, 10 μL of plasma or urine sample was mixed with 960 μL of the ABTS+ working solution
154 and after 4 min the absorbance at 734 nm was measured.

155 **2.5 Quantification of phenolic compounds in WPPs and plasma and urine samples**

156 The concentration of phenolic acids was measured using gas chromatography coupled to a triple quadrupole
157 mass spectrometry detection (GC/MS/MS) in WPPs, plasma and urine samples according to a method
158 previously described ¹¹. The identification and quantification of stilbenes, flavanols, and flavonols were
159 measured in the WPPs by High-performance liquid chromatography-diode-array detection (HPLC-DAD) as
160 previously described ¹⁵. Briefly, plasma samples (75 μL) were acidified (pH 4.6) and incubated with 10 μL of
161 β -glucuronidase (1000 U) with sulfatase activity (75 U) and 10 μL of β -glucosidase (10 U) during 4h at 37°C
162 to hydrolyze glucuronide, sulfate and glucoside metabolites. Urine samples (75 μL) followed the same
163 procedure as the plasma samples, but β -glucosidase was not added to the samples. The mixture was further
164 acidified (pH < 3) and extracted with ethyl acetate. After addition of 5% NaHCO₃, the bottom layer was
165 acidified and extracted again with ethyl acetate, and then dried under nitrogen. In addition, 1 mg of each
166 WPPs was extracted in methanol:formic acid (97:3, 25°C, 24h) and then dried under nitrogen. The dried
167 extracts were derivatized and then analyzed by GC-MS/MS for the determination of the phenolic acids.

168 **2.5.1 Gas chromatography–triple quadrupole mass spectrometry detection (GC/MS/MS)**

169 The samples (1mg of WPP or 75 μL of plasma or urine) were derivatized with 50 μL of BSTFA and 50 μL
170 of dry pyridine, mixed and heated at 40 °C for 30 min. The trimethylsilyl (TMS) derivatives were analyzed
171 with an Agilent 7890B GC System (Agilent Technologies, Inc., Palo Alto, CA) coupled to an Agilent 7010
172 GC/MS TripleQuad detector and fitted with an DB5-MS column (25 m x 0.20 mm, 0.33 μm film thickness,
173 Agilent Technologies) using helium as the carrier gas. The calibration curves were established by measuring
174 peak areas versus the responses in comparison with the internal standard 1-Hydroxy-2-naphthoic acid over a
175 range of analyte concentrations. The concentration of phenolic acids was finally expressed as $\mu\text{g/g}$ of both

176 red and white pomace product (rWPP or wWPP), μM for plasma samples and $\mu\text{mol}/\text{mmol}$ creatinine for
177 urine samples. Representative chromatograms are showed in Supplementary Figure 1 and Supplementary
178 Figure 2.

View Article Online
DOI: 10.1039/C9FO01743G

179 **2.5.2 Area under curve (AUC) calculation**

180 The area under the curve (AUC) of the graph of total phenolic acid content in the plasma samples over time
181 was calculated by the Trapezoid method ¹⁶.

182 **2.5.3 High-performance liquid chromatography-diode-array detection (HPLC-DAD)**

183 The WPPs was submitted to a liquid extraction (MeOH:Formic acid 97:3, 25°C, 24h) according to a
184 previously described method ¹⁵. The determinations were performed using analytical reversed-phase HPLC
185 on an Agilent 1100 series HPLC system (Agilent Technologies Inc., Palo Alto, CA, USA) coupled to a diode
186 array detector. A Spherisorb3® ODS2 reversed phase C18 column (250 mm x 4.6 mm, 3 μm particle size;
187 Waters S.A., Barcelona, Spain) was used for the determination of stilbens, flavanols and flavonols and, a
188 Nova-Pak reverse phase C18 column (250 mx x 4.6 mm, 4 μm particle size; Waters LTd., Elstree, U.K.) was
189 used for the anthocyanins analysis. For the stilbens, flavanols and flavonols analysis, the eluent was
190 monitored at 254, 280, 320, and 360, with the compound spectra between 220 and 600 nm. For the
191 anthocyanins assay, the eluent was monitored at 520 nm, with the compound spectra between 220 and 600
192 nm. Peak identification was performed by comparison of retention times and diode array spectral
193 characteristics with the standards. The results were expressed in $\mu\text{g}/\text{g}$ of WPP.

194 **2.6 Creatinine determination**

195 Levels of urinary creatinine were measured with the DetectX Urinary Creatinine Detection Kit (Arbor
196 Assays, Michigan, USA).

197 **2.7 Data presentation and statistical analysis**

198 The results were expressed as means \pm standard deviation of independent samples ($n=3$). Statistical analysis
199 was performed using Statgraphics® Centurion XVI, version 16.2.04 (Statpoint Technologies, Inc.,
200 Warranton, VA, USA). Significant differences between rWPP and wWPP were determined with the Student-
201 *t* test. One-way analysis of variance (ANOVA), using Fisher's least significant difference (LSD) test, was
202 used to determine significant differences between data from the plasma and urine concentrations of phenolic
203 acids and antioxidant capacity at the different doses and 2 hourly intervals. Linear correlations between the
204 plasma phenolic acid content and the antioxidant capacity after each assay and dose were evaluated by

205 Pearson's correlation coefficients, with the correlation significance determined by the Student-*t* test. A value
206 of $p < 0.05$ was applied to all analyses.

View Article Online
DOI: 10.1039/C9FO01743G

207

208 **3 Results and discussion**

209 Identification of phenolic compounds using GC/MS/MS and HPLC/DAD and antioxidant capacity (Q-FC,
210 Q-ABTS and Q-FRAP) were performed in the WPPs. Four different concentrations (50, 100, 150 and 300
211 mg/kg BW) of each WPP were orally administered to Wistar rats, in order to study their bioavailability, and
212 four sets of plasma and urine samples were collected at 2 h intervals (-2_0, 0_2, 2_4 and 4_6 hours). The
213 phenolic acids were identified and quantified and the antioxidant capacity was measured. The concentrations
214 evaluated in the present work were selected by the authors according to previous studies. The human
215 equivalent dose (HED) was also considered due to the potential use of the WPPs as a dietary supplement. All
216 doses were in the range of 0.5 – 3 g/day.

217 **3.1 Antioxidant capacity and phenolic composition of both the red Wine Pomace Product (rWPP) and** 218 **the white Wine Pomace Product (wWPP)**

219 As shown in the table 1, important differences in the antioxidant capacity and phenolic composition of both
220 the rWPP and the wWPP were observed. In agreement with other studies of grapes, wines, and wine pomace
221 extracts^{17–19}, the antioxidant capacity, assayed by Q-FC, Q-ABTS and Q-FRAP, was significantly higher
222 (2.1, 1.8, and 1.4 fold) in the rWPP than in the wWPP (Table 1).

223 A total of 16 phenolic acids were identified and quantified by GC/MS/MS and 5 anthocyanins, 5 flavanols, 4
224 flavonols, and 2 stilbenes were identified and quantified by HPLC/DAD. The sum of total phenolic
225 composition was about 2176 µg/g for the rWPP and of 781 µg/g for the wWPP (Table 1). In this sense, the
226 main difference between the two WPPs was the anthocyanins, since the sum of the rest of phenolic
227 compounds was 658 µg/g for rWPP and 781 µg/g for wWPP.

228 Flavonoids include different family subgroups (i.e. anthocyanins, flavanols, flavonols) that differ in the
229 degree of oxidation of their oxygenated heterocycle. Anthocyanins, the most abundant group in the rWPP
230 (1518 µg/g rWPP), were absent in the wWPP. This observation is important for the study of bioavailability,
231 because the anthocyanins can be metabolized by microbiota into phenolic acids such as syringic, vanillic,
232 protocatechuic, and coumaric acids, thereby contributing to the total content of phenolic acids in the plasma
233 samples²⁰. In the second place, the flavonols were the major compounds detected in both WPPs,

234 representing 48% and 36%, respectively, of all phenolic compounds (excluding anthocyanins), followed by
235 the flavanols (33% and 35% of the total) (Table 1). Flavonols and flavanols are known to be present in wine
236 pomace, mainly from skins and seeds ²¹. Furthermore, the procyanidins that are not extracted during the
237 winemaking process remain in the wine pomace and enrich its content of phenolic compounds. In our study,
238 the main flavonol was kaempferol-3-O-rutinoside at concentrations of 211 and 194 µg/g for the rWPP and
239 the wWPP, respectively, followed by other flavonols: myricetin-3-O-rhamnoside, kaempferol-3-O-glucoside
240 and quercetin-3-O-rutinoside. With respect to flavanols, epigallocatechin was the most abundant in both
241 WPPs (146 and 76.2 µg/g for rWPP and wWPP), followed by catechin, procyanidin B1, epicatechin, and
242 procyanidin B2. It is known that both flavonols and flavanols contribute to the total phenolic acid content of
243 plasma, and the procyanidins reach the colon intact, before they are degraded by the colon microbiota
244 resulting in the release of the flavanols monomers. Catechin and epicatechin (and their gallate esters,
245 epigallocatechin and epigallocatechin gallate) suffer further degradation by the colon microbiota including
246 hydrolysis of gallic acids from the galloylated forms, and C-ring fission producing dihydrophenyl-γ-
247 valerolactone and phenylvaleric acids. The progressive microbial catabolism of these two acids releases
248 different forms of phenyl and benzoic acids such as hydroxyphenylacetic, hydroxybenzoic, protocatechuic,
249 and gallic acids. Minor catabolites of flavanols by colon microbiota include hippuric, p-coumaric, vanillic,
250 homovanillic, 3-O-methylgallic, and syringic acids, among others ^{20,22,23}.

251 A significant difference in the content of stilbenes and phenolic acids was observed between the rWPP and
252 the wWPP (Table 1). The most abundant stilbene was resveratrol, significantly higher in rWPP (4.58 µg/g
253 product) than in the wWPP (1.21 µg/g product), while the total of phenolic acids was more abundant in the
254 wWPP (224 µg/g product) than in the rWPP (115 µg/g product). The most abundant phenolic acids were
255 gentisic and protocatechuic acids for the rWPP (27.9 and 18.1 µg/g product) and homoprotocatechuic and
256 caffeic acids for the wWPP (52.3 and 35.7 µg/g product). These phenolic compounds were also found in
257 other wine pomaces ^{24,25}, but in different concentrations, which may be due to the grape variety, winery
258 process, and even the presence of an extraction process ¹.

259 **3.2 Phenolic metabolite bioavailability in plasma after rWPP and wWPP intake**

260 The plasma levels of phenolic acid metabolites were assayed by GC/MS/MS and collected for each dose of
261 rWPP and wWPP at basal, 2, 4, and 6 hour post intake (Supplementary table 1).

262 The most abundant phenolic acids in the plasma samples after rWPP intake were hydroferulic, p-
263 hydroxyphenylacetic, syringic, and vanillic acids (12.0 μM , 6.7 μM , 5.2 μM and 4.8 μM , respectively) for
264 the four doses (50, 100, 150 and 300 mg/kg BW) (Figure 1A-D) and the highest levels were observed after
265 the dose of 100 mg/BW (Figure 1B). The high concentration of hydroferulic acid in plasma proceeds from
266 the colonic metabolism of several phenolic compounds present in the wine pomace principally anthocyanins,
267 ferulic and other cinnamic acids^{23,26}. Moreover, the principal type of phenolic compounds in the rWPP, the
268 anthocyanins, are metabolized in the upper gastrointestinal tract, and their metabolites include 4-
269 hydroxyhippuric and ferulic acids derivatives that reach their maximum in plasma at 1-1.5 hours after
270 consumption²⁷. In another hand, the highest levels observed for syringic and vanillic acids could be a
271 consequence of the microbial metabolism, in the large intestine, of the high content of malvidin and peonidin
272 present in the rWPP^{23,28}. Significant concentrations of m-hydroxyphenylacetic, protocatechuic,
273 homovanillic, gentisic, and caffeic acids were also observed after rWPP intake, but the rest of phenolic acids
274 were maintained at concentrations below 1 μM (Figure 1A-D and Supplementary table 1). It must be
275 highlighted that 80% of the metabolites under study increased in plasma when the intake was higher than 100
276 mg/kg BW compared to basal levels, while the intake of 50 mg/kg BW resulted in increases of 50% of the
277 metabolites after 2h (Supplementary table 1).

278 The main phenolic acids assayed in the plasma post-intake of wWPP showed that were m-
279 hydroxyphenylacetic, p-hydroxyphenylacetic, protocatechuic, and 4-O-methylgallic acids with values of 7.5
280 μM , 4.8 μM , 4.7 μM , and 4.4 μM (Figure 1E-H). In this case, m-hydroxyphenylacetic and protocatechuic
281 acids could derivate from hydrophenylvalerolactones and dihydroxyphenylpropionic acids produced by the
282 microbial catabolism of flavanols such as catechin, epicatechin, and procyanidin B2 that were predominant
283 in the wWPP^{22,23}. Significant concentrations of ferulic, homovanillic, vanillic, homoprotocatechuic, syringic,
284 and hydroferulic acids were observed, although all other metabolites had concentrations of less than 1 μM
285 (Supplementary table 1).

286 An increase of total phenolic acid metabolites in the plasma samples for all doses (50, 100, 150 and 300 mg/
287 kg BW) of rWPP was observed at 2h, 4h, and 6h after their intake (figure 2A). In this sense, 43% of the
288 phenolic metabolites after 2h of rWPP intake had their highest concentrations in the plasma samples, and
289 55% at 4h (figure 2A), suggesting absorption in the first part of the gastrointestinal tract and small intestine⁸.

290 Only 2% of the metabolites increased later on, suggesting that they were formed in the large intestine by

291 microbial metabolism²⁹. Furthermore, for the intake of 150 and 300 mg/kg BW doses of rWPP about a 44%
292 and 56% of all metabolites studied remained in the plasma after 4h until to 6h, while only 19% was observed
293 for doses of 50 and 100 mg/kg BW. In this respect, it is known that the half-life of phenolic metabolites
294 depends on both their stabilization by conjugation with plasma proteins and their eventual elimination
295 through of the biliary or urinary pathways. Urinary excretion is usually very low and in some cases showed a
296 second maximum peak in plasma, due to an enterohepatic circulation³⁰. In this case, a possible cumulative
297 effect observed for some flavonoid metabolites could be responsible for the maintenance of the high plasma
298 concentrations of phenolic acids.

299 The evaluation of the total phenolic plasma content over time in wWPP showed that 55% of the metabolites
300 reached the maximum level in the plasma samples at 2h after their intake (figure 2B), suggesting that
301 absorption was principally in the first part of the gastrointestinal tract and approximately 24 and 20% of the
302 metabolites had the peak plasma at 4h and 6h after wWPP intake. Likewise, the results of metabolite
303 evolution over time in the plasma sample after intake of wWPP showed differences between the lower dose
304 (50mg/kg BW) and the other doses (100, 150 and 300 mg /kg BW) (Supplementary table 1). For the intake
305 of 50 mg/BW occurs a decrease of 50% in the levels of plasma phenols at 2 and 4h, but the decrease for the
306 doses of 100, 150, and 300 mg/kg BW was lowest with percentages of 44%, 31%, and 31% respectively.
307 More importantly, after 2 h post-intake of doses of 150 and 300 mg/kg BW of wWPP a 38% of the phenolic
308 metabolites showed their highest levels in plasma, and approximately 25% of the metabolites continued to
309 increase at 4 h and 6 h for the dose of 150 mg/kg BW.

310 It indicates that the total phenolic acids in the plasma samples showed different behaviours for both the red
311 and the white WPPs (Supplementary table 1). In addition, with the purpose of comparing the total phenolic
312 acid content in the plasma for each dose, the area under the curve (AUC) of the total phenolic acid content in
313 the plasma samples over time was calculated (Figure 3A). A significant increase of the total metabolites of
314 the rWPP was observed for the dose of 100 and 150 mg/kg BW, but it was lower for the 300 mg/kg BW
315 dose. These results suggest that an increased intake of rWPP will not imply an increase of the total phenol
316 content in the plasma samples. In contrast, the metabolites significantly increased in the plasma samples at
317 higher doses of wWPP.

318 In summary, these results demonstrated that the bioavailability of wWPP phenolic acid in the plasma
319 samples was dose-dependent, but not for the rWPP. These results suggested an apparent saturation

320 mechanism for rWPP and not for wWPP, which was also reported in other studies for some polyphenols
321 after blueberry consumption ³¹. These differences can be explained by considering the different absorption,
322 excretion, and metabolic pathways of the WPPs, including different matrix compositions, which depend on
323 the major polyphenols of the WPP and possible interaction with plasma proteins.

View Article Online

DOI: 10.1039/C9FO01743G

324 **3.3 Phenolic metabolite elimination in urine after rWPP and wWPP intake**

325 p-hydroxyphenylacetic and vanillic acids were the phenolic acids excreted at the highest concentrations (2.2
326 and 1.9 $\mu\text{mol}/\text{mmol}$ creatinine) in the urine samples (Supplementary table 2), corresponding to the rWPP
327 doses of 100 and 150 mg/kg BW, respectively. These results agree with the observed for rWPP in plasma
328 where both polyphenols showed the highest values. Urine concentrations up to 0.1 μM were observed for
329 hydrocaffeic, hydroferulic, 4-O-methylgallic, 3,5-dihydroxy-4-methoxybenzoic, homovanillic, m-
330 hydroxyphenylacetic, isoferulic, protocatechuic, and ferulic acids principally for the 100 mg/kg BW dose.
331 Approximately 43% of the maximum urinary levels corresponds to the elimination at 4-6h post rWPP intake
332 (Figure 3B), which was in line with the appearance of metabolites in the plasma samples. At this point, it is
333 important to recall that polyphenol elimination can be through two pathways: renal and biliary. Taking these
334 into account, the levels of different phenolic acids in urine are dependent not only on their urinary excretion
335 ratio, but they also depend on their capacity to bind plasma proteins and the amount eliminated by biliary
336 excretion ³².

337 Maximum phenolic concentrations post wWPP intake were found for p-hydroxyphenylacetic acid
338 (0.9 $\mu\text{mol}/\text{mmol}$ creatinine) at a dose of 300 mg/kg BW dose (Supplementary table 1). Interestingly, this
339 phenolic acid was one of the highest concentrations of metabolites in the plasma samples. Urine levels of
340 dihydro-3-coumaric, gentisic, vanillic, ferulic, m-hydroxyphenylacetic, homovanillic, and protocatechuic
341 acids were higher than 0.1 μM , principally for the dose of 150 mg/kg BW. It is important to consider that
342 phenolic compounds underwent an intense phase II metabolism at intestinal epithelium and/or hepatic level
343 ³³. The highest excretion of the metabolites occurred at 2-4h post wWPP intake (Figure 3B) in agreement
344 with the peak plasma concentration of wWPP metabolites.

345 Thus, the differences between rWPP and wWPP were not only found in the profile of phenolic acids in the
346 plasma, but also they differed with regard to the time of maximum urinary elimination, which was probably
347 affected by the duration of the highest levels on plasma. The rWPP metabolites reached their maximum in

348 the plasma samples at 4h and in the urine samples at 4-6h, while the wWPP metabolites reached their
349 maximum earlier, at 2h in the plasma samples and at 2-4h in the urine samples.

View Article Online
DOI: 10.1039/C9FO01743G

350 In addition, the metabolites increased in both plasma and urine, but neither plasma nor urine is dose-
351 dependent for rWPP intake. Furthermore, not all individual metabolites exhibit dose relationship with intake
352 of WPP either in plasma or urine. Some metabolites (4-O-methylgallic, 3-O-methylgallic, hydrocaffeic,
353 dihydro-3-coumaric, gentisic, syringic acids) correlate with the amount of WPP ingested showing a linear
354 dose response. However, this does not apply to all polyphenol metabolites such as m-hydroxyphenylacetic,
355 vanillic, hydroferulic or p-hydroxyphenylacetic acids. Other studies of the polyphenol dose relationship with
356 metabolites neither showed dose relationship with metabolites analysis^{31,34,35}.

357 **3.4 Total Antioxidant capacity of plasma**

358 The biological properties of polyphenols present in the WPPs and their antioxidant activity depend on their
359 absorption, distribution, stability and metabolism². An important point to consider in the case of the wine
360 pomace products used in this study, is that they underwent no extraction.

361 The increase of ABTS values post wWPP (Figure 4B) was significative for all doses, while there was no
362 significative increase in the ABTS values for the rWPP (Figure 4A) during the time of the experiment. A
363 possible explanation could be found in the different phenolic acid profiles of the plasma samples after red or
364 white WPP intake. For example, the wWPP metabolites had higher contents of m-hydroxyphenylacetic,
365 protocatechuic, 4-O-methylgallic, homovanillic, and ferulic acids than rWPP and metabolites that can act as
366 a good scavenger of ABTS radicals. On the other hand, it is important to consider that some of the
367 metabolites can be conjugated, which might affect their antioxidant capacity⁷.

368 The ABTS values increased (between 8-30% with respect to the baseline) at 2h and 4h post wWPP intake for
369 all doses and at 6h only for the 150 and 300 mg/kg BW doses. The highest increase of ABTS values (30%)
370 was at 2h post intake of 300 mg wWPP /kg BW. This result is in agreement with the time of the highest level
371 of phenolic acid in plasma.

372 The ferric reducing capability of plasma (FRAP) increased post intake of 100 (at 2, 4 and 6h), 150, and 300
373 (4h) mg/kg BW of wWPP (Figure 4D) and no significant increase of FRAP was observed for the rWPP
374 (Figure 4C). The highest increase of FRAP values (20%) was at 4h post intake of 300 mg wWPP/kg BW.

375

376 **3.5 Correlations between the antioxidant capacity and the phenolic metabolites content in plasma**

377 There was a positive correlation (Table 2) between the antioxidant capacity of the plasma assayed by ABTS
378 and the total phenolic acids in the plasma samples after wWPP intake. A significant correlation ($p < 0.05$)
379 between the FRAP levels and the metabolites in the plasma was observed for the intakes of 100 and 300 mg
380 of wWPP/kg BW. In contrast, there was no significant correlation between the antioxidant capacity and the
381 metabolite levels in the plasma samples for the rWPP intake (table 2) where the highest level of phenolic
382 acids will not necessarily imply a higher antioxidant capacity, probably because of the metabolite profiles
383 and their bioactive form. A numerous of active mechanisms were not assayed, which could include
384 modulations of gene expression, enzymatic activities, and possible antioxidant activities inside the cells ^{36–38}.
385 In summary, the bioavailability of phenolic metabolites after rWPP intake in plasma and urine from Wistar
386 rats showed no dose effect. However, the intake of wWPP exhibited a dose effect, with major concentrations
387 of phenolic acid in plasma and urine metabolites after intake of 150 and 300 mg/BW. Furthermore, the
388 bioavailability of the wWPP phenolic acids occurs earlier than for the rWPP phenolic acids, as indicates the
389 maximum peak observed in plasma at 2 h post-intake for the wWPP and at 4 h post-intake for the rWPP.
390 Similarly, the urine levels of the wWPP observed in the plasma samples increased with the dose and the
391 metabolites of the rWPP decreased at the highest dose. The dose-dependent effect of the wWPP was
392 accompanied by a significant correlation between the phenolic metabolites in the plasma samples and their
393 antioxidant capacity.

394

395 **4 Abbreviations:** AUC, area under the curve; BW, body weight; WPPs, wine pomace products; rWPP, red
396 wine pomace product; wWPP, white wine pomace product.

397

398 **5 Chemical compounds studied in this article:** 3-O-methylgallic acid (PubChem CID: 19829); 4-O-
399 methylgallic acid (PubChem CID: 78016); caffeic acid (PubChem CID:689043); dihydro-3-coumaric acid
400 (PubChem CID: 91); ferulic acid (PubChem CID:445858); gentisic acid (PubChem CID:3469); homovanillic
401 acid (PubChem CID: 1738); homoprotocatechuic acid (PubChem CID: 547); hydrocaffeic acid (PubChem
402 CID: 348154); hydroferulic acid (PubChem CID: 14340); isoferulic acid (PubChem CID: 736186); m-
403 hydroxyphenylacetic acid (PubChem CID: 12122); p-hydroxyphenylacetic acid (PubChem CID:127);
404 protocatechuic acid (PubChem CID: 72); syringic acid (PubChem CID: 10742); vanillic acid (PubChem
405 CID: 8468).

406

407 6 Conflicts of interestView Article Online
DOI: 10.1039/C9FO01743G

408 The authors declare no conflict of interest.

409

410 7 Acknowledgments

411 The authors acknowledge financial support of the Ministry of Science, Innovation and Universities
412 (Research project PGC2018-097113-B-I00). The authors also thank Angelica Martinez Delgado for her
413 assistance in the experimental studies.

414

415 8 Supporting Information

416 Supplementary table 1, concentration (μM) of phenolic acid metabolites assessed by GC/MS/MS in plasma
417 after rWPP and wWPP intake. Supplementary table 2, concentration ($\mu\text{mol}/\text{mmol}$ creatinine) of phenolic
418 acid metabolites assessed by GC/MS/MS in urine after rWPP and wWPP intake. Supplementary Figure 1,
419 Representative GC/MS/MS chromatograms and list of analyzed compounds by multiple reaction monitoring
420 (MRM) segments, retention times, and precursor and product ions. Supplementary Figure 2, Representative
421 GC/MS/MS chromatograms and list of analyzed compounds in the red (A) and white (B) wine pomace
422 products.

423

424 9 References

- 425 1. Alonso AM, Guillén DM, Barroso BP, García A. Determination of Antioxidant Activity of Wine
426 Byproducts and Its Correlation with Polyphenolic Content. *J Agric Food Chem.* 2002;50:5832–6.
427 2. Chedea VS, Palade LM, Marin DE, Pelmus RS, Habeanu M, Rotar MC, et al. Intestinal Absorption
428 and Antioxidant Activity of Grape Pomace Polyphenols. *Nutrients.* 2018;10(588):1–24.
429 3. Kostyuk V, Potapovich A, Albuhaydar AR, Mayer W, De Luca C, Korkina L. Natural Substances for
430 Prevention of Skin Photoaging : Rejuvenation Res. 2018;21(2):91–101.
431 4. Cipolletti M, Fernandez VS, Montalesi E, Marino M, Fiocchetti M. Beyond the Antioxidant Activity
432 of Dietary Polyphenols in Cancer : the Modulation of Estrogen Receptors (ERs) Signaling. *Int J Mol*
433 *Sci.* 2018;19:2624.
434 5. Figueira I, Menezes R, Macedo D, Costa I, Nunes dos Santos C. Polyphenols Beyond Barriers : A
435 Glimpse into the Brain. *Curr Neuropharmacol.* 2017;15:562–94.
436 6. Kujawska M, Jodynys-Liebert J. Polyphenols in Parkinson ' s Disease : A Systematic Review of In
437 Vivo Studies. *Nutrients.* 2018;10(642):1–34.
438 7. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and
439 bioavailability. *Am J Clin Nutr.* 2004;79:727–47.
440 8. Castello F, Costabile G, Bresciani L, Tassotti M, Naviglio D, Luongo D, et al. Bioavailability and
441 pharmacokinetic profile of grape pomace phenolic compounds in humans. *Arch Biochem Biophys*
442 [Internet]. 2018;646(March):1–9. <https://doi.org/10.1016/j.abb.2018.03.021>
443 9. González-Centeno MR, Jourdes M, Femenia A, Rosselló C, Teissedre P-L. Characterization of

- 444 Polyphenols and Antioxidant Potential of White Grape Pomace Byproducts (*Vitis vinifera* L.). *J*
445 *Agric Food Chem.* 2013;61:11579–87. View Article Online
DOI: 10.1039/C9FO01743G
- 446 10. Mildner-Szkudlarz S, Bajerska J, Zawirska-Wojtasiak R, Górecka D. White grape pomace as a source
447 of dietary fibre and polyphenols and its effect on physical and nutraceutical characteristics of wheat
448 biscuits. *J Sci Food Agric.* 2012;
- 449 11. Del Pino-García R, Rivero-Pérez MD, González-SanJosé ML, Croft KD, Muñiz P. Bioavailability of
450 phenolic compounds and antioxidant effects of wine pomace seasoning after oral administration in
451 rats. *J Funct Foods.* 2016;25(2):486–96. <http://dx.doi.org/10.1016/j.jff.2016.06.030>
- 452 12. González-SanJosé, M. L., García-Lomillo, J., Del Pino-García, R., Muñiz-Rodríguez, P. and Rivero-
453 Pérez MD. Sazonador de origen vegetal con propiedades conservantes, sustitutivo de la sal, y
454 procedimiento de obtención del mismo. 2015. p. Spain Patent ES2524870 B.
- 455 13. Del Pino-García R, García-Lomillo J, Rivero-Pérez MD, González-SanJosé ML, Muñiz P. Adaptation
456 and Validation of QUick, Easy, New, CHEap, and Reproducible (QUENCHER) Antioxidant
457 Capacity Assays in Model Products Obtained from Residual Wine Pomace. *J Agric Food Chem.*
458 2015;63(31):6922–31.
- 459 14. Diehl K, Hull R, Morton D, Pfister R, Rabemampianina Y, Smith D, et al. A Good Practice Guide to
460 the Administration of Substances and Removal of Blood , Including Routes and Volumes.
461 2001;23(February 2000):15–23.
- 462 15. Del Pino-García R, González-SanJosé ML, Rivero-Pérez MD, García-Lomillo J, Muñiz P. The
463 effects of heat treatment on the phenolic composition and antioxidant capacity of red wine pomace
464 seasonings. *Food Chem.* 2017;221:1723–32.
- 465 16. Yeh S-T. Using Trapezoidal Rule for the Area under a Curve Calculation. *Proc 27th Annu SAS®*
466 *User Gr Int (SUGI'02).* 2002
- 467 17. Yildirim HK, Akçay YD, Güvenç U, Altindisli A, Sözmen EY. Antioxidant activities of organic
468 grape, pomace, juice, must, wine and their correlation with phenolic content. *Int J Food Sci Technol.*
469 2005;40:133–42.
- 470 18. Martins IM, Roberto BS, Blumberg JB, Chen CO, Macedo GA. Enzymatic biotransformation of
471 polyphenolics increases antioxidant activity of red and white grape pomace. *Food Res Int [Internet].*
472 2016;89:533–9. <http://dx.doi.org/10.1016/j.foodres.2016.09.009>
- 473 19. Vinson JA, Hontz BA. Phenol Antioxidant Index: Comparative Antioxidant Effectiveness of Red and
474 White Wines. *J Agric Food Chem.* 1995;43:401–3.
- 475 20. Fernandes I, Pérez-Gregorio R, Soares S, Mateus N, Freitas V De. Wine Flavonoids in Health and
476 Disease Prevention. *Molecules.* 2017;22(292):1–30.
- 477 21. García-Lomillo J, González-SanJosé ML. Applications of Wine Pomace in the Food Industry :
478 Approaches and Functions. *Compr Rev Food Sci Food Saf.* 2017;16:3–22.
- 479 22. Cueva C, Gil-Sánchez I, Ayuda-Durán B, González-Manzano S, González-Paramás AM, Santos-
480 Buelga C, et al. An Integrated View of the Effects of Wine Polyphenols and Their Relevant
481 Metabolites on Gut and Host Health. *Molecules.* 2017;22(99):1–15.
- 482 23. Mosele JI, Macià A, Motilva MJ. Metabolic and microbial modulation of the large intestine
483 ecosystem by non-absorbed diet phenolic compounds: A review. *Molecules.* 2015;20(9):17429–68.
- 484 24. Deng Q, Penner MH, Zhao Y. Chemical composition of dietary fiber and polyphenols of five
485 different varieties of wine grape pomace skins. *Food Res Int.* 2011;44(9):2712–20.
486 <http://dx.doi.org/10.1016/j.foodres.2011.05.026>
- 487 25. Jara-Palacios MJ, Hernanz D, Cifuentes-Gomez T, Escudero-Gilete ML, Heredia FJ, Spencer JPE.
488 Assessment of white grape pomace from winemaking as source of bioactive compounds , and its
489 antiproliferative activity. *Food Chem.* 2015;183:78–82.
- 490 26. Williamson G, Clifford MN. Role of the small intestine, colon and microbiota in determining the
491 metabolic fate of polyphenols. *Biochem Pharmacol.* 2017;139:24–39.
492 <http://dx.doi.org/10.1016/j.bcp.2017.03.012>
- 493 27. Ozdal T, Sela DA, Xiao J, Boyacioglu D, Chen F, Capanoglu E. The reciprocal interactions between
494 polyphenols and gut microbiota and effects on bioaccessibility. *Nutrients.* 2016;8(2):1–36.
- 495 28. Forester SC, Waterhouse AL. Gut Metabolites of Anthocyanins, Gallic Acid, 3-O-Methylgallic Acid,
496 and 2,4,6-Trihydroxybenzaldehyde, Inhibit Cell Proliferation of Caco-2 Cells. *J Agric Food Chem.*
497 2010;58:5320–7.
- 498 29. Del Rio D, Rodriguez-Mateos A, Spencer JPE, Tognolini M, Borges G, Crozier A. Dietary
499 (Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of Protective Effects
500 Against Chronic Diseases. *Antioxidants Redox Signal.* 2013;18(14):1819–92.

- 501 30. Scheepens A, Tan K, Paxton JW. Improving the oral bioavailability of beneficial polyphenols through
502 designed synergies. *Genes Nutr.* 2010;5:75–87. View Article Online
DOI: 10.1039/C9FO01743G
- 503 31. Feliciano RP, Mills CE, Ista G, Heiss C, Rodriguez-Mateos A. Absorption, Metabolism and
504 Excretion of Cranberry and Assessment of Inter-Individual Variability. *Nutrients.* 2017;9:268.
- 505 32. Crespy V, Morand C, Besson C, Cotellet N, Vézin H, Demigne C, et al. The splanchnic metabolism of
506 flavonoids highly differed according to the nature of the compound. *Am J Physiol Liver Physiol.*
507 2003;284:980–8.
- 508 33. Rodriguez A, David M, Christian V, Shanmuganayagam D, Reed J, Calani L, et al. Bioavailability,
509 bioactivity and impact on health of dietary flavonoids and related compounds: an update. *Arch
510 Toxicol.* 2014;88:1803–53.
- 511 34. Renouf M, Marmet C, Guy PA, Beaumont M. Dose-response plasma appearance of green tea
512 catechins in adults. *Mol Nutr.* 2013;57:833–9.
- 513 35. Park E, Edirisinghe I, Wei H, Vijayakumar LP, Banaszewski K, Cappozzo JC, et al. A dose –
514 response evaluation of freeze-dried strawberries independent of fiber content on metabolic indices in
515 abdominally obese individuals with insulin resistance in a randomized, single-blinded, diet-
516 controlled crossover trial. *Mol Nutr Food Res.* 2016;60:1099–109.
- 517 36. Del Pino-García R, Gerardi G, Rivero-Pérez MD, González-SanJosé ML, García-Lomillo J, Muñoz P.
518 Wine pomace seasoning attenuates hyperglycaemia-induced endothelial dysfunction and oxidative
519 damage in endothelial cells. *J Funct Foods.* 2016;22:431–45.
520 <http://dx.doi.org/10.1016/j.jff.2016.02.001>
- 521 37. Zhu F, Du B, Zheng L, Li J. Advance on the bioactivity and potential applications of dietary fibre
522 from grape pomace. *Food Chem.* 2015;186:207–12.
523 <http://dx.doi.org/10.1016/j.foodchem.2014.07.057>
- 524 38. Gerardi G, Cavia-Saiz M, Rivero-Pérez MD, González-SanJosé ML, Muñoz P. Modulation of Akt-
525 p38-MAPK/Nrf2/SIRT1 and NF-κB pathways by wine pomace product in hyperglycemic endothelial
526 cell line. *J Funct Foods.* 2019;58(May):255–65. <https://doi.org/10.1016/j.jff.2019.05.003>
- 527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557

558 TABLES

559

560

561

View Article Online

DOI: 10.1039/C9FO01743G

Table 1. Phenolic composition and antioxidant capacity of the rWPP and wWPP.

	$\mu\text{g/g}$ rWPP	$\mu\text{g/g}$ wWPP	
PHENOLIC COMPOUNDS	Phenolic acids		
	m-Hydroxyphenylacetic acid	3.10 \pm 0.17	4.10 \pm 0.45
	p-Hydroxyphenylacetic acid	3.19 \pm 0.23	14.9 \pm 0.46 *
	Vanillic acid	3.19 \pm 0.16	11.5 \pm 0.56 *
	Homovanillic acid	2.45 \pm 0.01	2.89 \pm 0.06 *
	Protocatechuic acid	18.1 \pm 1.50	7.79 \pm 0.13 *
	Homoprotocatechuic acid	13.9 \pm 0.10	52.3 \pm 2.46 *
	Gentisic acid	27.9 \pm 0.01	29.4 \pm 0.06 *
	Syringic acid	3.08 \pm 0.34	14.0 \pm 3.39 *
	4-O-methylgallic acid	1.16 \pm 0.01	2.48 \pm 0.31 *
	3-O-methylgallic acid	7.19 \pm 0.08	20.1 \pm 1.35 *
	Dihydro-3-coumaric acid	1.95 \pm 0.02	2.17 \pm 0.03 *
	Hydroferulic acid	2.24 \pm 0.01	5.19 \pm 0.09 *
	Hydrocaffeic acid	9.50 \pm 0.01	11.2 \pm 0.04 *
	Isoferulic acid	3.87 \pm 0.01	4.52 \pm 0.14 *
	Ferulic acid (trans-)	3.68 \pm 0.47	5.76 \pm 0.69 *
	Caffeic acid (trans-)	10.7 \pm 0.40	35.7 \pm 2.42 *
	<i>Total Phenolic acids^a</i>	115 \pm 1.08	224 \pm 7.00 *
	Stilbenes		
	t-piceid	0.64 \pm 0.11	0.63 \pm 0.02
	t-resveratrol	4.58 \pm 0.55	1.21 \pm 0.01 *
	<i>Total Stilbenes^a</i>	5.22 \pm 0.65	1.85 \pm 0.01 *
	Flavanols		
	Catechin	11.5 \pm 3.11	68.7 \pm 5.67 *
	Epigallocatechin	146 \pm 28.4	76.2 \pm 23.1 *
	Epicatechin	15.6 \pm 2.25	44.5 \pm 5.67 *
	Procyanidin B1	13.3 \pm 0.06	54.6 \pm 17.7 *
	Procyanidin B2	33.5 \pm 0.77	32.8 \pm 3.18
	<i>Total Flavanols^a</i>	220 \pm 24.5	277 \pm 5.28 *
	Flavonols		
	Myricetin-3-O-rhamnoside	50.9 \pm 2.76	27.9 \pm 2.43 *
	Kaempferol-3-O-rutinoside	211 \pm 19.7	194 \pm 31.9
Kaempferol-3-O-glucoside	32.8 \pm 2.98	29.8 \pm 3.47	
Quercetin-3-O-rutinoside	23.1 \pm 5.59	26.6 \pm 4.81	
<i>Total Flavonols^a</i>	318 \pm 28.0	278 \pm 32.3	
Anthocyanins			
Delphinidin-3-O-glucoside	244 \pm 22.3	ND *	
Cyanidin-3-O-glucoside	14.9 \pm 2.85	ND *	
Petunidin-3-O-glucoside	263 \pm 17.4	ND *	
Peonidin-3-O-glucoside	41.6 \pm 1.12	ND *	
Malvidin-3-O-glucoside	954 \pm 1.98	ND *	
<i>Total Anthocyanins^a</i>	1518 \pm 1.21	ND *	
Total Phenolic compounds^a			
<i>Q-FC (mg GAE/g WPP)</i>	20.2 \pm 0.08	9.50 \pm 0.05 *	
<i>Q-ABTS (mmol TE/g WPP)</i>	0.16 \pm 0.02	0.09 \pm 0.02 *	
<i>Q-FRAP (mmol Fe(II)Equivalent/g WPP)</i>	0.39 \pm 0.01	0.28 \pm 0.01 *	
TAC (Total Antioxidant Capacity)			

562

563

564

565

566

567

Table 1. Phenolic composition and antioxidant capacity of the red (rWPP) and white (wWPP) wine pomace products. Phenolic acid composition was assayed by GC/MS/MS. Stilbene, flavanol, flavonol and anthocyanin content were assayed by HPLC/DAD. The totals are the sum of each of the individual phenolic compounds. Values are expressed as $\mu\text{g/g}$ rWPP or wWPP. Antioxidant capacity was assayed by QUENCHER methods (Q-FC, Q-ABTS and Q-FRAP). Values are expressed as mg GAE/g WPP (Q-FC),

568 mmol TE/g WPP (Q-ABTS) and mmol Fe(II)/g WPP (Q-FRAP). Data are presented as mean \pm SD (n=3).
 569 Significant differences ($p < 0.05$) between rWPP and wWPP are indicated with an asterisk (*). ND not
 570 detected, Q-FC: QUENCHER-Folin-Ciocalteu, Q-ABTS: QUENCHER-ABTS, Q-FRAP: QUENCHER-
 571 FRAP, TAE: Tannic acid equivalent, TE: Trolox equivalent. rWPP: red wine pomace product, wWPP: white
 572 wine pomace product.

573

574 **Table 2. Correlations between the total phenolic content in plasma and the Total Antioxidant Capacity**
 575

	Dose (mg WPP/kg BW)	ABTS		FRAP	
		r	p	r	p
TOTAL PHENOLIC ACIDS	50	r	NSC	0.7314	NSC
		p		0.0069	
	100	r	NSC	0.6267	NSC
		p		0.0292	0.7563
	150	r	NSC	0.7719	NSC
		p		0.0033	
	300	r	NSC	0.7369	NSC
		p		0.0063	0.5783

576

577

578

579

580

581

582

583

584


585

586

587

Table 2. Correlation between the total phenolic content in the plasma samples and the antioxidant capacity assayed by the ABTS and the FRAP methods for both the red and white wine pomace products (rWPP and wWPP, respectively). The values represented the correlation coefficient (r) and probability ($p > 0.05$) between the total content of phenolic acids in plasma samples following oral administration to rats of 50, 100, 150 or 300 mg of both rWPP and wWPP/kg of body weight (BW), and the total antioxidant capacity of the plasma samples assayed by the ABTS and the FRAP methods. NSC: not significant correlation observed. rWPP: red wine pomace product. wWPP: white wine pomace product.

588



589




Figure 1. Radial representation of red (rWPP) and white (wWPP) pomace metabolites in plasma at basal and after 2h, 4h and 6h post intake for the doses of 50, 100, 150 and 300 mg/kg BW. (A-D) Concentration of the phenolic acid metabolites in the plasma samples ($n=3$) after red wine pomace product (rWPP) intake assayed by GC/MS/MS. Samples were collected at the indicated hours (plasma) pre- and post-administration of rWPP to rats at doses of 50 (A), 100 (B), 150 (C) or 300 (D) mg/kg of body weight (BW). Significant differences ($p < 0.05$) in the total phenolic content in plasma between basal, 2h, 4h and 6h for each dose are indicated with an asterisk (*). The main phenolic acid metabolites for each dose are shown in bold font. (E-H) Concentration of the phenolic acid metabolites in the plasma samples ($n=3$) after white wine pomace product (wWPP) intake assayed by GC/MS/MS. Samples were collected at the indicated hours (plasma) pre- and post-administration of wWPP to rats at doses of 50 (E), 100 (F), 150 (G) or 300 (H) mg/kg of body weight (BW). Significant differences ($p < 0.05$) in the total phenolic content in plasma between basal, 2h, 4h and 6h for each dose are indicated with an asterisk (*). The main phenolic acid metabolites for each dose are shown in bold font. rWPP: red wine pomace product, wWPP: white wine pomace product.

487x618mm (72 x 72 DPI)

Published on 08 January 2020. Downloaded by Universidad de Burgos on 1/8/2020 8:29:07 AM.

Food & Function Accepted Manuscript




Figure 2. (A) Percentage of red wine pomace (rWPP) metabolites in the plasma samples (n=3) with their highest concentration after 2, 4 or 6 hours post intake. The percentages represent the number of the individually rWPP metabolites that have a maximum level in plasma at 2h, 4h or 6h for all doses. (B) Percentage of white wine pomace (wWPP) metabolites in the plasma samples (n=3) with their highest concentration after 2, 4 or 6 hours post intake. The percentages represent the number of the individually rWPP metabolites that have a maximum level in plasma at 2h, 4h or 6h for all doses. rWPP: red wine pomace product, wWPP: white wine pomace product.

113x156mm (72 x 72 DPI)




Figure 3. (A) Area under the curve (AUC) of total phenolic acid content in plasma. The AUC values were calculated from the curves of the total phenolic metabolites present in the plasma samples in the 0-6h interval after 50, 100, 150 or 300 mg/kg of body weight (BW) administration to rats of the red (rWPP) and white (wWPP) pomace products. Data are presented as mean \pm SD ($n=3$). Significant differences ($p < 0.05$) in the AUC values between 50, 100, 150 and 300 mg of WPP/kg of body weight (BW) are indicated with Latin letters for the rWPP and with Greek letters for the wWPP. (B) Total phenolic metabolites in the urine samples of rats at basal (0h) and 2, 4 and 6 hours post intake of red (rWPP) or white (wWPP) wine pomace products. Data are presented as mean \pm SD, $n=3$. Significant differences ($p < 0.05$) are expressed in Latin letter for the rWPP and Greek letter for the wWPP. rWPP: red wine pomace product, wWPP: white wine pomace product.

179x219mm (72 x 72 DPI)




Figure 4. (A) Plasma ABTS values for the different doses (50, 100, 150, and 300 mg/kg Body Weight) administered to rats at basal (0h) and 2, 4 and 6 hours post intake of red wine pomace product (rWPP). (B) Plasma ABTS values for the different doses (50, 100, 150 and 300 mg/kg Body Weight) administered to rats at basal (0h) and 2, 4 and 6h post intake of white wine pomace product (wWPP). (C) Plasma FRAP values for the different doses (50, 100, 150 and 300 mg/kg BodyWeight) administered to rats at basal (0h), 2, 4 and 6 hours post intake of red wine pomace product (rWPP) in rats. (D) Plasma FRAP values for the different doses (50, 100, 150 and 300 mg/kg Body Weight) at baseline (0h), 2, 4 and 6 hours post intake of white wine pomace product (wWPP) in rats. Values are expressed as mmol TE/g WPP (ABTS) and mmol Fe(II)E/g WPP (FRAP). Data are presented as mean \pm SD (n=3). rWPP: red wine pomace product, wWPP: white wine pomace product, TE: Trolox equivalent.

414x269mm (72 x 72 DPI)